Pig kidney trial offers hope to thousands waiting for transplants

NCT ID NCT07224763

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This study is testing whether a kidney from a genetically modified pig can safely work in people with end-stage renal disease who cannot get a human kidney. Up to 50 participants will receive the pig kidney and be followed for at least 24 weeks to check survival, kidney function, and side effects. If it works, it could offer a new option for those with few alternatives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
genetically modified pig kidney with thymus tissue
What this could lead to
If successful, this could provide a new source of kidneys for people with end-stage renal disease who have few other options, potentially reducing waitlist deaths.
What could go wrong
This is an early-phase trial with only 50 participants, so results may not apply to everyone. Risks include organ rejection, infections from the pig tissue, and unknown long-term side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Nov 2076

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria for all Participants (Groups 1 and 2): 1. Provide voluntarily informed consent to participate in the study and for lifetime follow-up. 2. Have a diagnosis of ESRD at the time of informed consent. 3. Hemodialysis dependent for a minimum of 6 months and has a functioning arterial-venous fistula/graft or permanent catheter at the time of informed consent. 4. 50 to 70 years of age at the time of informed consent, or 40 to \<50 years of age with a calculated panel reactive antibody (cPRA) of ≥99.9%. 5. Evidence of thymic involution on chest computed tomography (CT) scan with a thymic region of interest score of ≤1. 6. Live within 3 hours travel time of the xenotransplant center. 7. Female participants must be postmenopausal or permanently sterilized (eg, hysterectomy, bilateral oophorectomy, or bilateral salpingectomy). Male participants must agree to the use of a highly effective method of birth control, if the possibility of conception exists. 8. Negative xeno-crossmatch at Screening and pre-transplant. 9. Estimated Post Transplant Survival Calculator score \>20%.(https://optn.transplant.hrsa.gov/data/allocation-calculators/epts-calculator/). 10. Body mass index ≤35 kg/m2. 11. Have completed or have initiated and plan to complete (meningococcal A, C, W, Y and meningococcal B vaccine series only) Centers for Disease Control and Prevention-recommended courses of age- and risk-factor-appropriate vaccinations. 12. Seropositive (immunoglobulin G) for cytomegalovirus and Epstein-Barr virus. Additional Inclusion Criteria for Group 1: 1\. Ineligible for conventional allogeneic kidney transplantation due to medical reason(s) for any of the following: 1. Ineligible for a living donor transplant. 2. Ineligible for an OPTN kidney transplant waitlist (reason for ineligibility will be collected). 3. Delisted from OPTN kidney transplant waitlist (reason for delisting will be collected). Additional Inclusion Criteria for Group 2: 1. On an OPTN kidney transplant waitlist (active or inactive status). 2. No approved living kidney donors. 3. More likely to die or go untransplanted within 5 years than receive a kidney transplant as measured by the Kidney Transplant Decision Aid at the time of informed consent (select United States for "Choose your state" field and National average for "Choose your transplant program" field; https://www.srtr.org/tools/kidney-transplant-decision-aid/). Exclusion Criteria (pertain to all participants in Groups 1 and 2): 1. Need for multiple organ transplants. 2. Severe medical co-morbidities including, but not limited to: 1. Chronic liver disease. 2. Advanced cardiovascular disease. 3. Severe peripheral vascular disease that limits technical ability to transplant the GGTA1 KO Thymokidney. 4. Severe neurologic diseases or conditions that would preclude meaningful recovery or informed consent. 5. Oral steroid-dependent airway disorder or chronic pulmonary disease or requires chronic, intermittent, or continuous supplemental oxygen. 6. Pulmonary hypertension. 7. Uncontrolled diabetes or sequelae of diabetes mellitus including severe non-proliferative diabetic retinopathy. 8. Severe neurogenic bladder that requires intermittent catheterization. 3. ESRD due to hereditary or structural kidney disease. 4. Active or recently treated malignancy at the time of informed consent. 5. Non-renal cause of hematological disorders associated with anemia (eg, thalassemia and sickle disease). 6. Cannot discontinue chronic anticoagulation therapy (low-dose daily aspirin is permissible). 7. History of major psychiatric disorders with psychiatric hospitalization and/or suicidal ideation within 5 years of informed consent. 8. Being treated for active tuberculosis (TB), have received prophylaxis for positive FDA-approved interferon-gamma release assay, or test positive for TB by FDA-approved interferon-gamma release assay test during Screening. 9. Nucleic acid test (NAT) positive for hepatitis B virus and/or hepatitis C virus, hepatitis B surface antibody (anti-HBs) titer \<10 mIU/mL unless the participant is determined to be a nonresponder to hepatitis B vaccination (a nonresponder is defined as having an anti-HB titer \<10 mIU/mL after having completed both the standard vaccine series and a fourth booster dose and/or second standard vaccine series), and/or positive for human immunodeficiency virus (HIV; HIV-1 and HIV-2 antibody and/or NAT). 10. Not able to independently perform activities of daily life. 11. Have a history of medical noncompliance that may preclude adherence to the demands and requirements of xenotransplantation (eg, history of substance use disorder \[SUD\] within 1 year of informed consent, lack of social support, untreated psychological conditions).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (end-stage renal disease) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • New York University Langone Health

    RECRUITING

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.